|
By
Josh Gee
|
|
Thursday, 25 June 2015 18:22 |
|
EXACT Sciences Corporation(NASDAQ:EXAS) has confirmed that it is expecting expects ending quarter two of the year with about 21,000 completed Cologuard tests.
|
|
Read more...
|
|
By
William Kent
|
|
Wednesday, 24 June 2015 15:00 |
 Speciality pharmaceutical firm Evoke Pharma Inc (NASDAQ:EVOK) has confirmed that the earlier revealed results from the Phase 2b clinical trial assessing EVK-001, the patented formulation of metoclopramide for relief of symptoms related to acute as well as recurrent diabetic gastroparesis in women, has been given in the July issue of the leading peer reviewed journal, Clinical Gastroenterology and Hepatogology.
|
|
Read more...
|
|
By
William Kent
|
|
Tuesday, 23 June 2015 14:51 |
 Manufacturer of virtual prosthetics, Second Sight Medical Products, which provides useful vision for blind patients, has confirmed three year results post-implant of the Argus II Retinal Prosthesis System from multi-center clinical trial.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Monday, 22 June 2015 14:03 |
 Biopharmaceutical firm Epizyme Inc. (NASDAQ:EPZM) has come out with results from Phase 1 of Tazemetostat, a first-in-class EZH2 inhibitor, demonstrating decent clinical activity when utilised as oral monotherapy in patients having advanced B-cell non-Hodgkin lymphomas as well as solid tumors.
|
|
Read more...
|
|
By
Staff and Wire Reports
|
|
Friday, 19 June 2015 15:26 |
 Industry leading therapeutic solutions firm Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) has confirmed developing cure for hepatitis B virus infection which the Phase II clinical trial of TKM-Ebola-Guinea has achieved.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Thursday, 18 June 2015 15:02 |
|
Shares of pharmaceutical firm Radius Health, which specialises in making products for treating osteoporosis, surged by over 17% today due to heavy trading after the firm came out with positive clinical data pertaining to investigational drug abaloparatide.
|
|
Read more...
|
|
By
William Kent
|
|
Tuesday, 16 June 2015 15:21 |
|
Avalanche Biotechnologies has confirmed that the Phase 2a clinical study for AVA-101 has completed objectives of 12-month primary endpoint showing that it was well tolerated having wet age-related macular degeneration.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Friday, 12 June 2015 19:29 |
 AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO) has confirmed receiving written feedback from U.S. Food and Drug Administration for a potential pivotal study for tivozanib in treating NRP-1 low colorectal cancer.
|
|
Read more...
|
|
By
Josh Gee
|
|
Thursday, 11 June 2015 15:00 |
|
GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH), which is focussed on developing as well as commercialising novel therapeutics from proprietary cannabinoid product platform has started second of two Phase 3 clinical trials of Epidiolex which treats Lennox-Gastaut syndrome. The LGS is a rare and severe form of childhood-onset epilepsy.
|
|
Read more...
|
|
By
Josh Gee
|
|
Wednesday, 10 June 2015 14:55 |
|
Vericel Corp. (NASDAQ:VCEL) confirms plans to submit Biologics License Application to FDA by 2015 end for treating Cartilage Defects in the Knee
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 3 of 12 |
